BUL:THQM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Tchaikapharma High Quality Medicines AD

Market Cap

лв1.2b

Last Updated

2021/07/28 22:12 UTC

Data Sources

Company Financials

Executive Summary

Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. More Details


Snowflake Analysis

Flawless balance sheet with questionable track record.

Share Price & News

How has Tchaikapharma High Quality Medicines AD's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: THQM is less volatile than 75% of BG stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: THQM's weekly volatility (1%) has been stable over the past year.


Market Performance


7 Day Return

0.7%

THQM

-0.9%

BG Pharmaceuticals

0.2%

BG Market


1 Year Return

16.0%

THQM

6.9%

BG Pharmaceuticals

25.3%

BG Market

Return vs Industry: THQM exceeded the BG Pharmaceuticals industry which returned 6.9% over the past year.

Return vs Market: THQM underperformed the BG Market which returned 25.3% over the past year.


Shareholder returns

THQMIndustryMarket
7 Day0.7%-0.9%0.2%
30 Day1.4%0.5%0.2%
90 Day2.8%10.4%-0.8%
1 Year16.0%16.0%10.3%6.9%27.5%25.3%
3 Year108.2%108.2%35.5%20.4%18.3%16.6%
5 Year243.6%243.6%47.8%22.5%50.1%39.1%

Long-Term Price Volatility Vs. Market

How volatile is Tchaikapharma High Quality Medicines AD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tchaikapharma High Quality Medicines AD undervalued compared to its fair value and its price relative to the market?

814.61x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: THQM (BGN14.5) is trading above our estimate of fair value (BGN0.45)

Significantly Below Fair Value: THQM is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: THQM is poor value based on its PE Ratio (814.6x) compared to the European Pharmaceuticals industry average (25.3x).

PE vs Market: THQM is poor value based on its PE Ratio (814.6x) compared to the BG market (24.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate THQM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: THQM is overvalued based on its PB Ratio (12.2x) compared to the XE Pharmaceuticals industry average (3.4x).


Future Growth

How is Tchaikapharma High Quality Medicines AD forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tchaikapharma High Quality Medicines AD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Tchaikapharma High Quality Medicines AD performed over the past 5 years?

-22.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: THQM has high quality earnings.

Growing Profit Margin: THQM's current net profit margins (3.3%) are lower than last year (3.8%).


Past Earnings Growth Analysis

Earnings Trend: THQM's earnings have declined by 22.5% per year over the past 5 years.

Accelerating Growth: THQM's earnings growth over the past year (1.8%) exceeds its 5-year average (-22.5% per year).

Earnings vs Industry: THQM earnings growth over the past year (1.8%) underperformed the Pharmaceuticals industry 7.8%.


Return on Equity

High ROE: THQM's Return on Equity (1.4%) is considered low.


Financial Health

How is Tchaikapharma High Quality Medicines AD's financial position?


Financial Position Analysis

Short Term Liabilities: THQM's short term assets (BGN74.3M) exceed its short term liabilities (BGN16.1M).

Long Term Liabilities: THQM's short term assets (BGN74.3M) exceed its long term liabilities (BGN3.4M).


Debt to Equity History and Analysis

Debt Level: THQM's debt to equity ratio (9.8%) is considered satisfactory.

Reducing Debt: THQM's debt to equity ratio has reduced from 12.3% to 9.8% over the past 5 years.

Debt Coverage: THQM's debt is well covered by operating cash flow (30.7%).

Interest Coverage: THQM earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Tchaikapharma High Quality Medicines AD current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate THQM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate THQM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if THQM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if THQM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: THQM is not paying a notable dividend for the BG market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of THQM's dividend in 3 years as they are not forecast to pay a notable one for the BG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Tchaikapharma High Quality Medicines AD has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tchaikapharma High Quality Medicines AD's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tchaikapharma High Quality Medicines AD
  • Ticker: THQM
  • Exchange: BUL
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: лв1.225b
  • Shares outstanding: 84.50m
  • Website: https://www.tchaikapharma.com

Number of Employees


Location

  • Tchaikapharma High Quality Medicines AD
  • 1 G. M. Dimitrov Boulevard
  • Sofia
  • 1172
  • Bulgaria

Listings


Biography

Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers alimentary tract and metabolism, anaesthetic, antibio...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/28 22:12
End of Day Share Price2021/07/28 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.